Crossmark

A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report

Crossref DOI link: https://doi.org/10.1007/s10637-022-01262-2

Published Online: 2022-06-06

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Chunguang

Chen, Shu

He, Qianru

Sun, Tingting

Xu, Peiran
License Information

Text and Data Mining valid from 2022-06-06

Version of Record valid from 2022-06-06
More Information

Article History

Received: 1 April 2022

Accepted: 24 May 2022

First Online: 6 June 2022

Change Date: 16 August 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10637-022-01292-w

Declarations

:

: The authors declared no conflicts of interest.

: All procedures performed in studies involving human participants comply with institutional and/or National Research Council ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: A written informed consent was obtained from the patient’s family for publication of the case details.

Updates are available Correction dated 2022-08-16

Click to view Correction: https://doi.org/10.1007/s10637-022-01292-w